CME/CE

Episodes 17-32 of 65

• 

  RestartResume

  Treating Patients With T2D and MASLD: Is the Tide Changing?

  RestartResume

  Treating Patients With T2D and MASLD: Is the Tide Changing?

  MinuteCE®

  Treating Patients With T2D and MASLD: Is the Tide Changing?

  1.00 program credit

  • 

    

    Naim Alkhouri, MD, FAASLD, DABOM

  1.00 program credit

• 

  RestartResume

  MASLD in My Clinic: Hiding in Plain Sight?

  RestartResume

  MASLD in My Clinic: Hiding in Plain Sight?

  MinuteCE®

  MASLD in My Clinic: Hiding in Plain Sight?

  1.00 program credit

  • 

    

    Robert H. Eckel, MD, FAHA, FACC, FNLA

  1.00 program credit

• 

  RestartResume

  You Want Me to Perform a Liver Stiffness Test in My Clinic, Did I Hear That Right?

  RestartResume

  You Want Me to Perform a Liver Stiffness Test in My Clinic, Did I Hear That Right?

  MinuteCE®

  You Want Me to Perform a Liver Stiffness Test in My Clinic, Did I Hear That Right?

  1.00 program credit

  • 

    

    Naim Alkhouri, MD, FAASLD, DABOM

  1.00 program credit

• 

  RestartResume

  I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis

  RestartResume

  I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis

  MinuteCE®

  I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis

  1.00 program credit

  • 

    

    Naim Alkhouri, MD, FAASLD, DABOM

  • 

    

    Tessa Janovsky, PA-C

  1.00 program credit

• 

  MinuteCE®

  Endocrinologists and PCPs: The Frontline Defense Against Cirrhosis in Patients with Type 2 Diabetes 

  1.00 credit 9 episodes

  • 

    

    Jeff McIntyre

  • 

    

    Naim Alkhouri, MD, FAASLD, DABOM

  • 

    

    Robert H. Eckel, MD, FAHA, FACC, FNLA

  • 

    

    Tessa Janovsky, PA-C

  1.00 credit 9 episodes

• 

  RestartResume

  M3: Managing the Cardiometabolic Risk in MASH

  RestartResume

  M3: Managing the Cardiometabolic Risk in MASH

  MinuteCE®

  M3: Managing the Cardiometabolic Risk in MASH

  1.00 program credit

  • 

    

    Robert H. Eckel, MD, FAHA, FACC, FNLA

  • 

    

    Naim Alkhouri, MD, FAASLD, DABOM

  1.00 program credit

• 

  RestartResume

  Noninvasive Tests for Clinically Significant Fibrosis: That's The Hepatologist's Job, Right?

  RestartResume

  Noninvasive Tests for Clinically Significant Fibrosis: That's The Hepatologist's Job, Right?

  MinuteCE®

  Noninvasive Tests for Clinically Significant Fibrosis: That's The Hepatologist's Job, Right?

  1.00 program credit

  • 

    

    Naim Alkhouri, MD, FAASLD, DABOM

  1.00 program credit

• 

  RestartResume

  It All Starts With a Patient

  RestartResume

  It All Starts With a Patient

  MinuteCE®

  It All Starts With a Patient

  1.00 program credit

  • 

    

    Jeff McIntyre

  1.00 program credit

• 

  RestartResume

  My Patient's At 'Low Risk' for Clinically Significant Fibrosis: What Should I Do Now?

  RestartResume

  My Patient's At 'Low Risk' for Clinically Significant Fibrosis: What Should I Do Now?

  MinuteCE®

  My Patient's At 'Low Risk' for Clinically Significant Fibrosis: What Should I Do Now?

  1.00 program credit

  • 

    

    Robert H. Eckel, MD, FAHA, FACC, FNLA

  1.00 program credit

• 

  RestartResume

  Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice

  RestartResume

  Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice

  CME/CE

  Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice

  0.25 credits

  • 

    

    Hongya Chen, PharmD

  • 

    

    Jennifer Day, PharmD

  • 

    

    Keith C. Ferdinand, MD

  0.25 credits

• 

  RestartResume

  ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy

  RestartResume

  ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy

  CME/CE

  ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy

  0.25 credits

  • 

    

    Marianna Fontana, MD

  • 

    

    Ronald Witteles, MD

  0.25 credits

• 

  RestartResume

  Beyond the Horizon: HELIOS Clinical Trials in ATTR Cardiomyopathy  

  RestartResume

  Beyond the Horizon: HELIOS Clinical Trials in ATTR Cardiomyopathy  

  CME/CE

  Beyond the Horizon: HELIOS Clinical Trials in ATTR Cardiomyopathy  

  • 

    

    Marianna Fontana, MD

• 

  RestartResume

  Overcoming Clinical Inertia in Hyperkalemia Management

  RestartResume

  Overcoming Clinical Inertia in Hyperkalemia Management

  CME/CE

  Overcoming Clinical Inertia in Hyperkalemia Management

  0.25 credits

  • 

    

    Peter Rossing, MD, DMSc

  • 

    

    Michael Böhm, MD, FESC

  • 

    

    Luca De Nicola, MD, PhD

  0.25 credits

• 

  RestartResume

  Getting to the Root of CKD-Associated Pruritus: Questions From the Field

  RestartResume

  Getting to the Root of CKD-Associated Pruritus: Questions From the Field

  CME/CE

  Getting to the Root of CKD-Associated Pruritus: Questions From the Field

  0.25 credits

  • 

    

    Joel Topf, MD

  • 

    

    James Burton, DM, FRCP

  0.25 credits

• 

  RestartResume

  Curbside Consult: Optimizing IgAN Management

  RestartResume

  Curbside Consult: Optimizing IgAN Management

  CME/CE

  Curbside Consult: Optimizing IgAN Management

  0.25 credits

  • 

    

    Khalil El Karoui, MD

  • 

    

    Federico Alberici, MD, PhD

  0.25 credits

• 

  RestartResume

  Beyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program

  RestartResume

  Beyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program

  CME/CE

  Beyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program

  • 

    

    Dmitry M. Yaranov, MD

• Previous
• 1
• 2
• 3
• 4
• 5
• Next